Publication: 87

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

Citation:: Leukemia vol 25 (5)

Year:: 2011
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 432
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: U10 CA047577, U10 CA032291, CA33601, CA77597, CA04457, CA101140, CA11789, U10 CA077658, CA02599, CA77406, CA47577, CA47555, CA32291, CA29165, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, CA26806, CA45389, CA45808, CA35279, CA12046, CA35421, CA16450, U10 CA101140, CA77440, U10 CA041287, CA45564, CA04326, CA08025, CA74811, CA21060, CA47559, CA47642, CA45418, CA77658, CA37135, CA77298, CA31983, CA31946, U10 CA003927, CA07968

Corr. Author:
Authors:: MR Baer SL George BL Sanford K Mrózek JE Kolitz JO Moore RM Stone BL Powell MA Caligiuri CD Bloomfield RA Larson

Networks:

Study: CALGB-9720
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: acute myeloid leukemia, age, daunorubicin, dose escalation, etoposide